Anfomed

Anfomed is a Munich-based biotechnology company focused on developing novel small molecule therapeutics for the treatment of chronic inflammatory and autoimmune diseases. The company's primary research centers on the inhibition of Salt-Inducible Kinases (SIK), specifically SIK2 and SIK3, which play a crucial role in regulating immune cell function and cytokine production. By targeting these kinases, Anfomed aims to restore immune homeostasis and provide more effective treatment options for conditions such as inflammatory bowel disease. Founded as a spin-off from the Ludwig Maximilian University of Munich, the company is backed by prominent life science investors including Forbion and BioGeneration Ventures. The leadership team combines deep expertise in kinase biology and drug discovery to advance their pipeline toward clinical development.